ZIOPHARM Oncology’s (ZIOP) “Hold” Rating Reiterated at Zacks Investment Research

Zacks Investment Research reaffirmed their hold rating on shares of ZIOPHARM Oncology (NASDAQ:ZIOP) in a research note released on Saturday morning.

According to Zacks, “ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. “

A number of other research firms have also recently issued reports on ZIOP. BidaskClub upgraded ZIOPHARM Oncology from a strong sell rating to a sell rating in a report on Thursday, January 4th. ValuEngine cut ZIOPHARM Oncology from a sell rating to a strong sell rating in a report on Sunday, December 31st. HC Wainwright restated a buy rating and set a $9.50 price target on shares of ZIOPHARM Oncology in a report on Tuesday, November 7th. Finally, Raymond James Financial restated a hold rating on shares of ZIOPHARM Oncology in a report on Monday, December 11th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. ZIOPHARM Oncology currently has a consensus rating of Hold and a consensus price target of $12.67.

ZIOPHARM Oncology (NASDAQ ZIOP) opened at $4.36 on Friday. The stock has a market capitalization of $618.96, a P/E ratio of -8.38 and a beta of 1.44. ZIOPHARM Oncology has a twelve month low of $3.77 and a twelve month high of $7.88.

ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.13). The business had revenue of $1.60 million for the quarter, compared to the consensus estimate of $1.66 million. ZIOPHARM Oncology’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.11) earnings per share. equities analysts forecast that ZIOPHARM Oncology will post -0.54 EPS for the current year.

In other news, CEO Laurence James Neil Cooper bought 6,440 shares of the business’s stock in a transaction that occurred on Wednesday, November 8th. The shares were bought at an average cost of $4.68 per share, for a total transaction of $30,139.20. Following the acquisition, the chief executive officer now directly owns 1,083,731 shares in the company, valued at $5,071,861.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 10.40% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in shares of ZIOPHARM Oncology by 7.6% in the 2nd quarter. Vanguard Group Inc. now owns 7,864,470 shares of the biotechnology company’s stock worth $48,917,000 after purchasing an additional 553,933 shares in the last quarter. State Street Corp lifted its holdings in shares of ZIOPHARM Oncology by 12.8% in the 2nd quarter. State Street Corp now owns 4,556,264 shares of the biotechnology company’s stock worth $28,342,000 after purchasing an additional 517,057 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of ZIOPHARM Oncology by 10.1% in the 2nd quarter. Northern Trust Corp now owns 1,630,858 shares of the biotechnology company’s stock worth $10,144,000 after purchasing an additional 149,067 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in shares of ZIOPHARM Oncology by 6.6% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 618,589 shares of the biotechnology company’s stock worth $3,799,000 after purchasing an additional 38,440 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in shares of ZIOPHARM Oncology by 2.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 611,533 shares of the biotechnology company’s stock worth $3,804,000 after purchasing an additional 13,127 shares in the last quarter. Institutional investors own 40.23% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/16/ziopharm-oncologys-ziop-hold-rating-reiterated-at-zacks-investment-research.html.

ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Get a free copy of the Zacks research report on ZIOPHARM Oncology (ZIOP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply